Milligan Michael Lee
See Remarks
Milligan Michael Lee has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 19, 2026.
On the most recent filing, Milligan Michael Lee is listed as See Remarks at Neumora Therapeutics, Inc. Inside the rolling window, Milligan Michael Lee reported no open-market purchases and 1 open-market sale totaling $5K in NMRA.
Companies traded
Other insiders at NMRA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Milligan Michael Lee made?
Milligan Michael Lee has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Milligan Michael Lee trade?
Milligan Michael Lee has filed SEC Form 4 disclosures for 1 company, including NMRA.
When was Milligan Michael Lee's most recent SEC Form 4 filing?
Milligan Michael Lee's most recent SEC Form 4 filing on Tracefour is dated Feb 19, 2026.
What is Milligan Michael Lee's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Milligan Michael Lee is listed as See Remarks.
What is Milligan Michael Lee's total buy and sell value in the current window?
Inside the rolling retention window, Milligan Michael Lee bought $0 and sold $5K based on SEC Form 4 filings.
What was Milligan Michael Lee's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,436 NMRA shares on 2026-02-17, worth $5K, per SEC Form 4 filings.